top border
top border
Featured Programs
PD-L1 Expression as a Biomarker in RCC
The panelists, Nizar M. Tannir, MD, FACP; Carlos H. Barrios, MD; Susanne Osanto, MD, PhD; Daniel Heng, MD, MPH, FRCPC; and Paul Nathan, MBBS, PhD, FRCP, address PD-L1 expression as a potential biomarker for selecting renal cell carcinoma (RCC) treatment. View Now

In this segment, Dean F. Bajorin, MD, and Evan Y. Yu, MD, discuss atezolizumab in muscle-invasive bladder cancer. View Now

 

Immunotherapy and Oncology

Anti-Angiogenic Therapy in Lung and GI Cancers

Anti-Angiogenic Therapy in Lung and GI Cancers
Mark Socinski, MD, moderates this OncLive Peer Exchange panel discussion on modern use of anti-angiogenic therapy. The experts in gastrointestinal and lung cancers include Johanna C. Bendell, MD; Edward Garon, MD; Roy Herbst, MD; Yelena Y. Janjigian, MD; and Manish Shah, MD.
View Now
Vincent T. DeVita Jr MD
In The Death of Cancer, written by Vincent T. DeVita Jr, MD, a pioneering oncologist reveals, after 50 years on the front lines of medicine, why the war on cancer is winnable, and how to get there.
Publication Bottom Border
Border Publication